NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

iclight,

None of the data in this trial is "useless" (your word not mine). I believe PFS will finally be able to be effectively measured and correlated to OS by the end of this trial and OS benefit leads to approval sooner than later. I think regulators will eventually adopt measures used in this trial for future trials which will lead to shortened trials and reduced discovery costs for immunotherapy trials. Best wishes.